Evidence map›Paper›PMID 30884828›Full record

ArticleCancers2019

Mutated

Victoria Neumeyer, Michael Vieth, Markus Gerhard, Raquel Mejías-Luque

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. JAK-STAT1 Signaling Pathway Is an Early Response toInternational journal of molecular sciences · 2022
    Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Victoria NeumeyerInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, 81675 Munich, Germany. victoria.neumeyer@tum.de.
Michael ViethInstitut für Pathologie, Klinikum Bayreuth, 95445 Bayreuth, Germany. vieth.lkpathol@uni-bayreuth.de.
Markus GerhardInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, 81675 Munich, Germany. markus.gerhard@tum.de.ORCID 0000-0001-9110-3950
Raquel Mejías-LuqueInstitut für Medizinische Mikrobiologie, Immunologie und Hygiene, Technische Universität München, 81675 Munich, Germany. raquel.mejias-luque@tum.de.ORCID 0000-0002-4602-4927
Technical University of Munich · DEBayreuth Medical Center · DE

Funding

Deutsche Forschungsgemeinschaft GE2042 12-1
6 · The paper itself

Abstract

The E3 ubiquitin ligase ring finger protein 43 (RNF43) is frequently mutated in gastric tumors and loss of RNF43 expression was suggested to be one of the key events during the transition from adenoma to gastric carcinoma. Functional studies on RNF43 have shown that it acts as a tumor suppressor by negatively regulating Wnt signaling. Interestingly, we observed that RNF43

Indexed as

gastric pathologyH. pyloriRNF43

Identifiers

PMID30884828
PMCPMC6468876
OpenAlexW2921927143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.